House Democrats Target Trump Drug Pricing in Oversight Push — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- House Democrats have vowed to aggressively pursue oversight if they win control of the House or Senate in November's midterm elections, with health care and President Trump's drug pricing deals identified as potential targets.
- Flipping either chamber would give Democrats subpoena authority, enabling them to compel testimony from Trump administration officials and company executives and force responses to inquiries.
- The Trump administration could forcefully push back against Democratic-led oversight, according to the source.
- Parties traditionally turn to oversight when they seize a congressional chamber because it allows them to frame a narrative about the opposing side while sidestepping intraparty divisions.
- Oversight offers Democrats a way to keep Trump at the center of political attention even though he cannot run for president again.
Why it matters: A Democratic flip of either chamber would hand them subpoena power to haul administration officials and drug company executives before Congress, but the source flags that the administration is prepared to resist — setting up a direct confrontation over health care accountability heading into the next presidential cycle.
Ask SkimNews
